Clinical Trials
2 trialsNCT04837196 2025-08-08
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
Astellas Pharma Inc
Phase 1/2 Completed
NCT04949191 2024-09-19
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
Incyte Corporation
Phase 2 Terminated